Giving the Immune System a Boost in Cancer With DPP4 Inhibitors

Scientists at Institut Pasteur in France have repurposed DPP4 inhibitors, used to treat type 2 diabetes mellitus, to boost the body's immune response to tumors.

While immuno-oncology agents like the PD-1 and PD-L1 inhibitors have revolutionized cancer care by preventing checkpoint blockade, scientists at the Institut Pasteur have discovered another way to manipulate the body's immune response to a tumor—increased infiltration of T-cells to the tumor site.

In their article published in Nature Immunology, the authors show that inhibition of the enzyme dipeptidylpeptidase 4 (DPP4), also a target in diabetes, helps boosts the body's immune response to a tumor by maintaining the activity of CXCL10 and CXCR3 receptors. Preserving the activity of these receptors helps the influx of immune cells at the tumor site, which can help reject tumor growth.

Read more on ScienceDaily: http://bit.ly/1L2zU7v